Zoomedia Blog
All Blogs:
Zoomedia recently had the privilege to spend a day with the Multiple Myeloma Research Foundation discussing challenges and strategies to help the organization advance its mission to fund research and bring patients to the center of the drug development process.
Tags: Patient Strategy, MMRF
Wait, hold onto your tux!! Now that the Oscars are over why not put your tux to better use at the ALF Salute to Excellence Awards Gala, the annual black tie event honoring those who have made an outstanding contribution to biotechnology and medical innovation. The event has been held annually for ten years and to date has raised more than $3 million dollars. The honorees this year include Hollings C. Renton, Chairman, President and Chief Executive Officer, Onyx Pharmaceuticals, Inc, Frank McCormick, PhD, FRS, Co-Founder of Onyx Pharmaceuticals, Inc., Samuel So, MD, FACS, Director, Asian Liver Center, Director, Liver Cancer Program, The Lui Hac Minh Professor of Surgery, Stanford University School of Medicine with special recognition going to Mark G. Edwards, Managing Director of Recombinant Capital, Inc.
Tags: Patient Strategy
I am the CEO of a communications agency that depends directly on DTC and DTP advertising for a significant portion of our bottom line. One of our largest clients is a non-profit patient advocacy group. In addition, we have many, many clients who have to balance their passion for finding cures with their need to satisfy their investors' expectations. As we begin 2008 and listen to the Presidential candidates views on healthcare, we hear a lot of strident voices within industry often pitted against patient advocacy. It seems that there's a lot of talk about change, a lot of serious resistance to change, and a lot of skeptics who say the pharmaceutical industry will never change.
Yesterday, Dr. Judah Folkman, the pioneering cancer researcher whose passion and commitment resulted in a whole new field of medicine, died.
Tags: Product Strategy, Global Strategy, Oncology
Many of our clients have asked us recently about “Web 2.0” technologies. Pharma DTC websites are beginning to see lively discussion around this topic and the technological advances behind the terminology are significant. Web 2.0, and all that the label stands for, indicates a major directional shift in online communication between all the stakeholders involved in DTC and DTP promotion. There is a significant patient empowerment movement emerging fueled by Web 2.0 that biotech and pharma cannot afford to ignore. This month we will address the Health 2.0 movement, its associated Web 2.0 terminology and technologies, and weigh-in on the debate many Biotechnology and Pharmaceutical companies are having about how, or whether, to best use these technologies. This is a very new form of communication particularly as applied to DTC promotion. In coming months, we will be publishing a series of articles and newsletters around social networking as it relates to our highly-regulated industry and the Health 2.0 movement.
Tags: Patient Strategy, Global Strategy, Product Strategy, Transforming Technology, Web 2.0
